ZetaGen Therapeutics

Pharmaceutical ManufacturingNew York, United States2-10 Employees

Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company pioneering novel therapies for metastatic and primary breast cancers. Using proprietary carriers with a single intratumoral injection, Zetagen delivers tumoricidal therapies that minimize off-target side effects while improving survival. Founded in 2015 and based at the Central New York Biotech Accelerator (CNYBAC), the company has earned two FDA Breakthrough Designations and built a robust IP portfolio with 70+ issued patents, including multiple Composition-of-Matter patents. Zetagen recently completed a Phase 2a study with its lead candidate, supported by peer-reviewed publications demonstrating clinical efficacy. Growth has been funded through Series A & B rounds and Phase I & II NIH/NCI grants.
The pipeline includes:
ZetaMet™ (Zeta-BC-003): Targets metastatic breast cancer in bone, halting lytic activity, reducing pain, and regenerating bone via a single intratumoral injection. A Phase 2a trial at the University of British Columbia showed Complete Response, full bone regeneration, and no skeletal-related events; preliminary results will be presented at SABCS.
ZetaMast™ (Zeta-MBC-005): A hydrogel delivering two synergistic tumoricidal agents for breast cancer liver metastases. Designed to localize treatment and reduce systemic toxicity, preclinical results (published in PLOS ONE, co-authored by Dr. Debu Tripathy) demonstrated reduced tumor burden, prevention of soft tissue metastases, and improved survival. A Phase 1b dose-escalation study is planned for 1H-2026.
ZetaPrime™ (Zeta-PBC-007): A neo-adjuvant intratumoral therapy using a proprietary lipid carrier for controlled release of two small molecules, including a novel entity or CDK4/6 inhibitor. Targeting primary breast cancer, it aims to reduce surgeries, radiation, and off-target effects. In vivo studies showed superior survival and tumor suppression versus Tamoxifen and Verzenio; results will be presented at SABCS.

Sign up for free to view info

Email Format Employee directory